Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases
Phase 3
- Conditions
- Colorectal CancerLiver Metastases
- Interventions
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 584
- Registration Number
- NCT04525326
Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Diagnostic Test: Multi-omics
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT04525807
Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 10
- Registration Number
- NCT04524884
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
Phase 3
Recruiting
- Conditions
- Ovarian Cancer
- Interventions
- Drug: Etoposide, Cyclophosphamide, Carboplatin/Cisplatin
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 590
- Registration Number
- NCT04520074
- Locations
- 🇨🇳
Wu Xiaohua, Shanghai, Shanghai, China
Laparoscopic Sleeve Gastrectomy Under General Anesthesia in Severely Obese Patients: a Retrospective Study
- Conditions
- Obesity
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT04521543
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT04520035
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Xuhui, China
Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
Not Applicable
Recruiting
- Conditions
- Esophageal Squamous Cell CarcinomaChemoradiotherapySurvival
- Interventions
- Radiation: radiotherapy
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 320
- Registration Number
- NCT04519905
- Locations
- 🇨🇳
Fudan Universtiy Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Huadong Hospital, Shanghai, Shanghai, China
🇨🇳Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer
Phase 2
Active, not recruiting
- Conditions
- Thyroid Cancer
- Interventions
- Drug: multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 115
- Registration Number
- NCT04521348
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer
Phase 2
Completed
- Conditions
- Locally Advanced Rectal Cancer
- Interventions
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 130
- Registration Number
- NCT04518280
- Locations
- 🇨🇳
Shanghai Changhai Hospital, Shanghai, Shanghai, China
🇨🇳Zhen Zhang, Shanghai, Shanghai, China
🇨🇳Shanghai East Hospital, Shanghai, China
Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Radiation: IMRT to the nasopharynx and neckDrug: Adjuvant chemotherapy with Capecitabine
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT04517214
- Locations
- 🇨🇳
Xiaomin Ou, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath